Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Cancer Vaccines01:30

Cancer Vaccines

340
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneous trajectories of appendicular skeletal muscle mass change and cognitive impairment in community-dwelling middle-aged and older adults.

Scientific reports·2026
Same author

Nitrogen vacancies g-C<sub>3</sub>N<sub>4</sub>/BiOBr S-scheme heterojunction with Pd for efficient photocatalytic H<sub>2</sub>O<sub>2</sub>production.

Nanotechnology·2026
Same author

Target-Centric Multiplexed Screening of an Herbal Extract Identifies a Novel Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonist for Cancer Immunotherapy.

ACS central science·2026
Same author

Tandem Auxochrome Design Enables Ready Access to Deep Shortwave Infrared Dyes.

Journal of the American Chemical Society·2026
Same author

A genomic compendium of hundreds of teleost fishes reveals their evolutionary landscape.

Innovation (Cambridge (Mass.))·2026
Same author

Highly Doped Tm<sup>3+</sup> Nanoparticles with Efficient 1632 nm Emission Enable High-Fidelity Multiplexing In Vivo Bioimaging.

Nano letters·2026

Related Experiment Video

Updated: Jun 6, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

811

CAR-armored-cell therapy in solid tumor treatment.

Yan Liu1, Lin Xiao1, Mingxuan Yang1

  • 1Navy Medical University, Shanghai, 200433, China.

Journal of Translational Medicine
|November 28, 2024
PubMed
Summary

Chimeric antigen receptor (CAR)-T cell therapy shows promise for cancer, but CAR-NK and CAR-M cells offer new strategies for solid tumors. This study explores their potential and challenges for improved cancer immunotherapy.

Keywords:
CAR-MCAR-NKCAR-TSolid tumor

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.2K

Related Experiment Videos

Last Updated: Jun 6, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

811
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.2K

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Engineering

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment by genetically engineering T cells to target tumors.
  • Challenges like poor tumor infiltration and immunosuppressive microenvironments limit CAR-T cell efficacy in solid tumors.

Purpose of the Study:

  • To discuss the features, advantages, and limitations of CAR-T, CAR-NK, and CAR-M cells in treating solid tumors.
  • To explore prospective solutions for enhancing CAR host-cell-based immunotherapies.

Main Methods:

  • Review of current literature on CAR-T, CAR-NK, and CAR-M cell therapies.
  • Comparative analysis of their mechanisms, efficacy, and challenges in solid tumor treatment.

Main Results:

  • CAR-T cells face significant hurdles in solid tumors, including trafficking and the tumor microenvironment (TME).
  • CAR-NK cells offer potential advantages like HLA compatibility and reduced toxicity.
  • CAR-M cells demonstrate phagocytic capabilities and antigen presentation for solid tumor targeting.

Conclusions:

  • CAR-NK and CAR-M cells represent promising complementary strategies to overcome CAR-T cell limitations in solid tumors.
  • Further research is needed to optimize CAR host-cell-based immunotherapies for enhanced solid tumor treatment efficacy.